Completed × Hodgkin Disease × Melphalan × Clear all
NCT04191187 2025-12-11

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
34 enrolled 14 charts
NCT03096782 2023-10-11

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
6 enrolled 10 charts
NCT02960646 2023-02-16

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
11 enrolled
NCT01010217 2020-03-25

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

M.D. Anderson Cancer Center

Phase 2 Completed
176 enrolled 18 charts
NCT00856388 2019-11-13

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Roswell Park Cancer Institute

Phase NA Completed
62 enrolled 14 charts
NCT00003396 2019-10-17

Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

University of Maryland, Baltimore

Phase 2 Completed
42 enrolled
NCT01529827 2019-09-24

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

Phase 2 Completed
94 enrolled 11 charts
NCT01008462 2019-06-11

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Fred Hutchinson Cancer Center

Phase 2 Completed
16 enrolled 15 charts
NCT00238433 2017-09-27

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

OHSU Knight Cancer Institute

Phase 2 Completed
37 enrolled 8 charts
NCT00691015 2017-06-28

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
48 enrolled 12 charts
NCT01471067 2017-04-28

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
33 enrolled
NCT00683046 2016-11-22

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

University of Chicago

Phase 2 Completed
204 enrolled 7 charts
NCT00589563 2014-09-10

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

City of Hope Medical Center

Phase 2 Completed
32 enrolled 24 charts
NCT00060255 2013-05-09

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

Roswell Park Cancer Institute

Phase 2 Completed
451 enrolled
NCT00003425 2013-04-26

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

University of Kentucky

Phase 1/2 Completed
25 enrolled
NCT00002750 2013-02-20

Melphalan in Patients With Neoplastic Meningitis

Duke University

Phase 1 Completed
6 enrolled
NCT00027937 2010-05-14

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Completed